Huons said Wednesday that it has acquired a patent regarding the manufacturing method for Clacier, a dry eye treatment, in China.
Clacier is a cyclosporine single nano eye drop that is transparent and does not require shaking. Such aspects make it convenient for patients to use the treatment.
The company, who jointly filed the patent with Yonsei University, has already registered patents in Korea, U.S., Europe, Japan, Australia, Russia, and Singapore. The company has also received sales approval in Korea, Latin America, and the Middle East, including Saudi Arabia.
Huons plans to complete phase 3 clinical trials and receive sales approval for Clacier as soon as possible and accelerate distribution in China with Interlims, its Chinese partner. The two companies had previously signed a partnership agreement in March.
“We have been steadily acquiring overseas patents to show our advanced eye drop technology to the world,” Huons CEO Um Key-an said. “The acquisition of the patent in China is part of the process,”
The company plans to acquire patents in Thailand and use it as a bridgehead for the entering into the Southeast Asian market.
According to global market research institutes, the global market for dry eye syndrome is worth approximately four trillion won ($3.7 billion) and shows an annual growth rate of 7 percent.
<© Korea Biomedical Review, All rights reserved.>